High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4 weeks after starting therapy and amino acid substitutions in the hepatitis C virus in patients infected with HCV genotype 1b

Hidenori Toyoda,Takashi Kumada,Seiki Kiriyama,Makoto Tanikawa,Yasuhiro Hisanaga,Akira Kanamori,Toshifumi Tada,Takahiro Arakawa,Masashi Fujimori,Takuro Niinomi,Naoto Ando,Satoshi Yasuda,Keisuke Sakai,Jun Kimura

High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4 weeks after starting therapy and amino acid substitutions in the hepatitis C virus in patients infected with HCV genotype 1b

2011

Hidenori Toyoda
Takashi Kumada
Seiki Kiriyama
Makoto Tanikawa
Yasuhiro Hisanaga
Akira Kanamori
Toshifumi Tada
Takahiro Arakawa
Masashi Fujimori
Takuro Niinomi
Naoto Ando
Satoshi Yasuda
Keisuke Sakai
Jun Kimura

Background The ability to predict the outcome of peginterferon (PEG-IFN) and ribavirin combination therapy based on the reduction in hepatitis C virus (HCV) RNA levels at 4 weeks after starting the therapy and amino acid substitutions in HCV was to be confirmed.

Keywords:

Hepatitis C virus
RNA
Genotype
Amino acid
Virology
Ribavirin
Combination therapy
Medicine
Hepatology
high ability
Diabetes mellitus
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations